Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Director departure Appointed director
|
Predictive Oncology Inc. (AIPT)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
08/10/2023 |
8-K
| Quarterly results
Docs:
|
"Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, August 10th, at 5:30pm EDT PITTSBURGH, Aug. 10, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023. Q2 2023 and Recent Highlights: Initiated PEDAL-Cancer Research Horizons collabor..." |
|
08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
05/15/2023 |
8-K
| Quarterly results
Docs:
|
"Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 5:30pm EDT EAGAN, Minn., May 15, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three months ended March 31, 2023, and provided a corporate update. The company reported a net loss of $3.4 million on total net revenue of $0.2 million for the first quarter 2023. Q1 2023 and Recent Highlights: Announced groundbreaking partnership with Cancer Research Ho..." |
|
05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/08/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
05/02/2023 |
8-K
| Quarterly results |
04/20/2023 |
8-K
| Quarterly results |
04/05/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
03/29/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
03/21/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data
Docs:
|
"Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update EAGAN, Minn., March 21, 2023 -- Predictive Oncology Inc. , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments laboratory and Good Manufacturing Practices facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update. The company reported a net loss of $25.7 million on total net revenue of $1.5 million for the full year. 2022 Highlights: Successfully completed Discovery 21, establishing proof-of-concept for the PEDAL™ drug discover..." |
|
03/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
03/17/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
03/16/2023 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
03/16/2023 |
8-A12G
| Form 8-A12G - Registration of securities [Section 12(g)]: |
03/14/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
03/13/2023 |
8-K
| Other Events Interactive Data |
02/03/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs:
|
"Predictive Oncology Appoints Pamela Bush, Ph.D., MBA, as Chief Business Officer EAGAN, Minn., Feb. 03, 2023 -- Predictive Oncology Inc. is pleased to announce the appointment of Pamela Bush, Ph.D., MBA, as Chief Business Officer. Dr. Bush will lead all business development, partnering and growth strategies for Predictive Oncology. As a key member of the executive team, Dr. Bush will spearhead the company’s strategic, operational and financial planning initiatives for both existing customers and emerging new markets. She will work closely with the company’s senior management in leveraging and expanding its portfolio of proprietary solutions to advance drug discovery and enable oncology drug development for the company’s biopharma partners. “In terms of scientific intelligence, industry insi..." |
|
12/05/2022 |
8-K
| Quarterly results |
12/02/2022 |
8-K
| Quarterly results |
11/10/2022 |
8-K
| Quarterly results |
11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
11/10/2022 |
8-K
| Quarterly results |
10/25/2022 |
8-K
| Quarterly results |
10/20/2022 |
8-K
| Quarterly results |
10/18/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
10/18/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
10/14/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
10/13/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
09/30/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
09/16/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
09/14/2022 |
8-K
| Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits ... |
08/11/2022 |
8-K
| Quarterly results |
08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
|
|
|